Syndax Pharmaceuticals, Inc.

NasdaqGS:SNDX Rapport sur les actions

Capitalisation boursière : US$1.7b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Syndax Pharmaceuticals Gestion

Gestion contrôle des critères 2/4

Syndax Pharmaceuticals' CEO is Michael Metzger, appointed in Feb 2022, has a tenure of 2.5 years. total yearly compensation is $9.13M, comprised of 7.4% salary and 92.6% bonuses, including company stock and options. directly owns 0.062% of the company’s shares, worth $1.05M. The average tenure of the management team and the board of directors is 2.2 years and 8.1 years respectively.

Informations clés

Michael Metzger

Directeur général

US$9.1m

Rémunération totale

Pourcentage du salaire du PDG7.4%
Durée du mandat du directeur général2.5yrs
Propriété du PDG0.06%
Durée moyenne d'occupation des postes de direction2.2yrs
Durée moyenne du mandat des membres du conseil d'administration8.1yrs

Mises à jour récentes de la gestion

Recent updates

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04
Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20
Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27
Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Aug 07

Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Apr 08

Analyse de la rémunération des PDG

Comment la rémunération de Michael Metzger a-t-elle évolué par rapport aux bénéfices de Syndax Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$264m

Mar 31 2024n/an/a

-US$241m

Dec 31 2023US$9mUS$678k

-US$209m

Sep 30 2023n/an/a

-US$176m

Jun 30 2023n/an/a

-US$160m

Mar 31 2023n/an/a

-US$153m

Dec 31 2022US$4mUS$640k

-US$149m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

US$818k

Mar 31 2022n/an/a

US$15m

Dec 31 2021US$3mUS$594k

US$25m

Sep 30 2021n/an/a

-US$92m

Jun 30 2021n/an/a

-US$91m

Mar 31 2021n/an/a

-US$86m

Dec 31 2020US$2mUS$577k

-US$77m

Sep 30 2020n/an/a

-US$71m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$61m

Dec 31 2019US$3mUS$540k

-US$56m

Sep 30 2019n/an/a

-US$61m

Jun 30 2019n/an/a

-US$65m

Mar 31 2019n/an/a

-US$69m

Dec 31 2018US$2mUS$506k

-US$74m

Sep 30 2018n/an/a

-US$74m

Jun 30 2018n/an/a

-US$72m

Mar 31 2018n/an/a

-US$67m

Dec 31 2017US$1mUS$492k

-US$61m

Rémunération vs marché: Michael's total compensation ($USD9.13M) is above average for companies of similar size in the US market ($USD5.62M).

Rémunération et revenus: Michael's compensation has increased whilst the company is unprofitable.

PDG

Michael Metzger (53 yo)

2.5yrs

Titularisation

US$9,127,419

Compensation

Mr. Michael A. Metzger is a Director at Pyxis Oncology, Inc since June 10, 2024. Mr. Metzger has experience in the biopharmaceutical sector, is serving as Chief Executive Officer and as a member of the Boa...

Équipe de direction

NomPositionTitularisationCompensationPropriété
Michael Metzger
CEO & Director2.5yrsUS$9.13m0.062%
$ 1.1m
Neil Gallagher
President1.3yrsUS$4.04m0.015%
$ 261.5k
Keith Goldan
CFO, Treasurer & Chief Accounting Officer2.2yrsUS$2.83m0.021%
$ 351.2k
Luke Albrecht
Senior VP8yrsUS$2.59m0.051%
$ 862.2k
Catherine Madigan
Chief Medical Officer2.4yrsUS$2.81m0.042%
$ 720.1k
Peter Ordentlich
Co-Founder & Chief Scientific Officer18.8yrspas de données0.00031%
$ 5.3k
Richard Heyman
Co-Founderno datapas de donnéespas de données
Ronald Evans
Co-Founderno datapas de donnéespas de données
Michael Downes
Co-Founderno datapas de donnéespas de données
Sharon Klahre
Vice President of Investor Relations & Communications2.2yrspas de donnéespas de données
Kevin McManus
Chief People Officer1.3yrspas de donnéespas de données
Joseph Eder
Member of Scientific Advisory Board & Chief Medical Officer1.7yrspas de donnéespas de données

2.2yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: SNDX's management team is considered experienced (2.2 years average tenure).

Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Michael Metzger
CEO & Director5.1yrsUS$9.13m0.062%
$ 1.1m
Ronald Evans
Co-Founder8.1yrspas de donnéespas de données
Joseph Eder
Member of Scientific Advisory Board & Chief Medical Officer8.1yrspas de donnéespas de données
Keith Katkin
Independent Director7.4yrsUS$581.02k0.038%
$ 637.7k
Pierre Legault
Independent Director7.6yrsUS$575.59k0.038%
$ 637.7k
Dennis Podlesak
Independent Chairman15.7yrsUS$1.10m0.017%
$ 287.6k
George Sledge
Member of Scientific Advisory Board7.3yrsUS$23.05kpas de données
Jedd D. Wolchok
Member of Scientific Advisory Board8.1yrspas de donnéespas de données
Hope Rugo
Member of Scientific Advisory Board8.1yrspas de donnéespas de données
Samir Khleif
Member of Scientific Advisory Board8.1yrspas de donnéespas de données
Julie Brahmer
Member of Scientific Advisory Board8.7yrspas de donnéespas de données
Lisa Coussens
Member of Scientific Advisory Board7.6yrspas de donnéespas de données

8.1yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: SNDX's board of directors are considered experienced (8.1 years average tenure).